COLUMBIA CITY, Ind., Feb. 12, 2025 /PRNewswire/ — Nanovis, a leading developer and provider of nano surface technology that improves the biologic fixation of orthopedic, spine, and dental implants, announced today that certain of its nano surface technology assets and certain of its rights to intellectual property assets related to Sites Medical’s OsteoSync™ titanium pads, have been acquired by Medtronic for use in the development of Medtronic’s next generation PEEK interbody fusion devices.
“We are excited about our collaboration with Medtronic,” said Brian More, CEO of Nanovis. “Combining our market-leading nano surface technology with Medtronic’s market-leading PEEK implant designs will give a growing number of surgeons access to best-in-class devices to treat patients.”
The FDA-designated bone-growth nanotechnology has been shown to improve the speed and consistency of the human bone-growth response. It enhances implant fixation through osseointegration which is the process where bone grows and fuses with the surface of a spinal implant.
“This collaboration is a testament to the significance of the nano surface technology we developed and the value it delivers to our customers and to patients,” said More. “Medtronic’s commitment to innovation and commercial scale makes them an ideal partner to take these technologies to market.”
About Nanovis
Nanovis, ( www.nanovistechnology.com ) focused on the company’s four pillars of healing, engineers and manufactures nano surface technologies to improve the biologic fixation of orthopedic, spinal, and dental implants. The company has developed a market leading nanotube surface technology that has been shown to improve osseointegration of titanium implants.
Nanovis was the first to market with an FDA nanotechnology designation on an enhanced PEEK interbody which includes porous titanium endplates made from OsteoSync™ provided by Sites Medical and the first to market with an FDA nanotechnology designation on pedicle screws.
SOURCE Nanovis